Considering that cytokine targeting in HLH is important, recently the JAK1/2 inhibitor ruxolitinib has been shown effective in mouse models of HLH, inhibiting IFN-γ, IL-6, and IL-12 secretion and improving clinical symptoms [91]. The gene discussed is IL6; the disease is hemophagocytic syndrome.